PharmEnable supports early drug discovery programs by providing a rapid, cost efficient, and effective platform to identify new hit candidates. They use their unique and diverse virtual compound library in conjunction with our computational screening programs, to identify novel active chemical starting points against the most challenging biological targets
Location: United Kingdom, England
Total raised: $9.99M
Investors 6
| Date | Name | Website |
| - | o2h ventur... | o2hventure... |
| - | Syndicate ... | syndicater... |
| - | Cambridge ... | cambridgea... |
| - | Parkwalk A... | parkwalkad... |
| 22.06.2023 | MP Healthc... | mp-healthc... |
| - | Martlet | martletcap... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.05.2023 | Seed | $7.5M | - |
| 30.06.2020 | - | $2.49M | - |
Mentions in press and media 12
| Date | Title | Description |
| 22.05.2023 | PharmEnable Closes $7.5M Financing led by MP Healthcare to Develop Next Generation of Small Molecule Drugs to Treat Cancer and Neurological Diseases | - |
| 22.05.2023 | PharmEnable closes $7.5m funding round to scale drug hunt | - |
| 22.05.2023 | PharmEnable Closes $7.5M Pre-Series Financing | PharmEnable, a Cambridge, UK-based drug discovery company focused on chemical novelty, diversity and complexity, closed a $7.5M Pre-Series A funding round. The round was led by MP Healthcare Venture Management, the venture arm of Mitsubishi... |
| 22.05.2023 | Mitsubishi backs PharmEnable in £6m pre-Series A | Drug discovery startup PharmEnable has secured $7.5m (£6m) in a pre-Series A raise led by Mitsubishi Tanabe Pharma Group’s venture capital division, MP Healthcare. The Cambridge-based biotech has developed an “AI-powered” drug discovery tec... |
| 22.09.2021 | Introducing: the 32 companies joining the Applied AI programme in 2021 | We are excited to announce the 32 AI companies selected for the third iteration of Tech Nation’s Applied AI growth programme. Companies accepted into the newest cohort are also applying AI to create real-world impact in the fields of data ... |
| 16.07.2021 | PharmEnable and LifeArc partner to discover novel oral antiviral drugs to treat coronaviruses | PharmEnable and LifeArc partner to discover novel oral antiviral drugs to treat coronaviruses 16-07-2021 PharmEnable, an AI drug discovery company unlocking challenging biological targets, announces that it has entered into a drug discovery... |
| 15.07.2021 | LifeArc and PharmEnable team up to discover novel oral antiviral drugs to treat coronaviruses | Cambridge, UK, 15 July 2021 – PharmEnable, an AI drug discovery company unlocking challenging biological targets, announces that it has entered into a drug discovery collaboration with LifeArc, an independent UK medical research charity, to... |
| 12.01.2021 | Sosei Heptares and PharmEnable collaborate for AI-driven drug discovery against challenging GPCR target | Sosei Heptares and PharmEnable collaborate for AI-driven drug discovery against challenging GPCR target 12-01-2021 Sosei Group Corporation and PharmEnable, a UK drug discovery company, announce they have entered a collaboration to apply the... |
| 30.06.2020 | Cambridge spin-out PharmEnable raises £1.8m for drug discovery expansion | PharmEnable, a Cambridge-based drug discovery company using advanced medicinal chemistry and AI-enabled approaches to design the next generation of highly complex and specific drug candidate molecules, announces it has closed a £1.8 million... |
| 30.06.2020 | Cambridge spin-out PharmEnable raises £1.8m for drug discovery expansion | Cambridge spin-out PharmEnable raises £1.8m for drug discovery expansion 30-06-2020 PharmEnable, a Cambridge-based drug discovery company using advanced medicinal chemistry and AI-enabled approaches to design the next generation of highly c... |
Show more